Research Analysts Offer Predictions for PDS Biotechnology Co.’s FY2028 Earnings (NASDAQ:PDSB)

PDS Biotechnology Co. (NASDAQ:PDSB) – Investment analysts at HC Wainwright issued their FY2028 earnings estimates for PDS Biotechnology in a report issued on Wednesday, March 27th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of $0.33 per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.43) per share.

PDSB has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of PDS Biotechnology in a research note on Friday, January 12th. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, March 16th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, PDS Biotechnology currently has an average rating of “Moderate Buy” and an average target price of $17.67.

PDS Biotechnology Price Performance

PDSB stock opened at $3.85 on Thursday. The company’s fifty day simple moving average is $5.26 and its 200 day simple moving average is $5.10. PDS Biotechnology has a 12-month low of $3.61 and a 12-month high of $10.27. The firm has a market cap of $119.77 million, a price-to-earnings ratio of -2.25 and a beta of 1.72. The company has a quick ratio of 6.21, a current ratio of 6.21 and a debt-to-equity ratio of 0.96.

Hedge Funds Weigh In On PDS Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. EP Wealth Advisors LLC purchased a new stake in PDS Biotechnology in the third quarter worth about $52,000. Vontobel Holding Ltd. lifted its holdings in shares of PDS Biotechnology by 28.1% during the 3rd quarter. Vontobel Holding Ltd. now owns 41,000 shares of the company’s stock valued at $207,000 after buying an additional 9,000 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of PDS Biotechnology in the 3rd quarter worth approximately $56,000. Corton Capital Inc. bought a new stake in shares of PDS Biotechnology during the 3rd quarter valued at $112,000. Finally, Raymond James & Associates bought a new stake in PDS Biotechnology during the third quarter valued at about $123,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.